Introduction
Tumor necrosis factor a (TNFa) is a multifunctional cytokine that initiates a wide variety of biological responses. TNFa acts as a host defense factor in immunological responses and participates in target cell destruction mediated by cytotoxic T cells (Baker and Reddy, 1998) . The cytokine is cytotoxic for several tumor cell lines, although the vast majority of transformed and normal cell types are resistant to TNFainduced death. Most of the pro-apoptotic biological effects of TNFa are transduced through TNFR1 (Wallach et al., 1999) , a receptor that, similar to CD95, contains a conserved intracellular region, known as the death domain (DD). The DD region is essential for the cytotoxicity as it mediates the binding of DDcontaining adaptor proteins and the subsequent activation of cysteine proteases, caspases, which are the crucial executioners of apoptosis. Upon ligand binding, the adaptor protein TNFR1-associated death domain (TRADD) binds to the cytoplasmic portion of TNFR1 and associates via its DD with the DD of the adaptor Fas-associated death domain (FADD)/MORT1 (Boldin et al., 1995; Chinnaiyan et al., 1996) . FADD recruits caspase-8 via death effector domain interaction and this results in caspase-8 activation by proximity-induced autoprocessing (Boldin et al., 1996; Muzio et al., 1996; Salvesen and Dixit, 1999 ). Active caspase-8 then proteolytically activates downstream effector caspases, such as caspase-3, -6 and -7 (Muzio et al., 1997) . Effector caspases finally cleave various cellular substrates and thereby induce apoptotic cell death Essmann et al., 2000; Wieder et al., 2001a) . TNFa also induces ceramide production by the activation of sphingomyelinases, which in turn can trigger caspases through the mitochondrial pathway of apoptosis .
Caspase-8 activation provides a link between death receptor signaling and the mitochondrial pathway of apoptosis, thereby amplifying the receptor signal (Luo et al., 1998; Belka et al., 2000; Daniel et al., 2003) . Caspase-8 induces the proapoptotic cleavage of the Bcl-2-related protein Bid, which triggers Bax activation (Eskes et al., 2000; Ruffolo et al., 2000) , mitochondrial release of cytochrome c and mitochondrial permeability shift transition. In the cytosol, cytochrome c binds to the adaptor protein APAF-1, an event which leads to the activation of the initiator caspase-9 (Li et al., 1997) . The relevance of this mechanism is underlined by the recent observation that TNFa may promote apoptosis through a Bid-dependent conformational change in Bax that is inhibited by adenoviral E1B 19K (Perez and White, 2000) .
In most cell types, TNFa induces not only an apoptotic response but also the simultaneous activation of NF-kB, a transcription factor that counteracts cell death by the expression of antiapoptotic genes (Smirnov et al., 2001) . TNFa activates NF-kB by recruiting the proteins TNF receptor activating factor-1 and -2 (TRAF1 and TRAF2) and the DD-containing kinase receptor-interacting protein (RIP) to TNFRI-bound TRADD (Carpentier et al., 1998; Carpentier and Beyaert, 1999; Guiet et al., 2002; Wallach et al., 2002) . These receptor-initiated signals lead to the activation of the IkB kinase (IKK) complex comprising two catalytical subunits, IKKa and b, as well as the regulatory subunit IKKg/NEMO (Prajapati and Gaynor, 2002) . IKK-induced phosphorylation of the NF-kB inhibitory protein IkB results in its polyubiquitination and degradation (Regnier et al., 1997; Yaron et al., 1998) . This pathway exerts a significant antiapoptotic effect by regulating the transcription of target genes such as IEX-1 L , TRAF1/2, cIAP-1/-2, A20 and the Bcl-2 members Bcl-x L and A1 (Carpentier et al., 1998; Carpentier and Beyaert, 1999; De Valck et al., 1999; Beyaert et al., 2000; Wallach et al., 2002) . In addition, NF-kB induces expression of proteins of the TNF receptor complex (Heyninck and Beyaert, 2001 ). Nevertheless, NF-kB activation is considered to be the main mechanism opposing TNFa-induced cytotoxicity (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wallach et al., 2002) .
In the present study, we analysed the mechanisms of TNFa-induced cellular responses and apoptosis in malignant hematological cells. We found that TNFa itself is not cytotoxic in the investigated myeloid leukemic and Hodgkin cells, but markedly sensitizes these cells to death induced by chemotherapeutic drugs. At first sight, this effect is similar to the TNFa homolog TRAIL that sensitizes a broad variety of cancer cells for drug-induced apoptosis through a caspase-8/Bid-dependent pathway (Peter, 2000; de Almodovar et al., 2001; El-Deiry, 2001 ; Kontny et al., 2001; MacFarlane et al., 2002; Milner et al., 2002; Xiang et al., 2002) . This sensitization by TRAIL occurs via a Bcl-2/Bax-dependent mitochondrial pathway (Fulda et al., 2002; Kim et al., 2002) . Here we show, however, that the sensitizing effect by TNFa does not involve a caspase-8-dependent mechanism. Nevertheless, TNFa mediated the enhancement of mitochondrial alterations, including loss of the mitochondrial membrane potential and cytochrome c release. Furthermore, although inhibition of NF-kB increased drug-induced apoptosis, it did not modulate the effect of TNFa. Thus, our results suggest that TNFa sensitizes cells to drug-induced apoptosis and activates the mitochondrial pathway through an NF-kB-and caspase-8-independent mechanism.
Results

TNFa sensitizes HD-MyZ cells to etoposide-, epirubicinand ceramide-induced apoptosis
TNFa did not induce cell death in HD-MyZ cells at concentrations up to 100 ng/ml and incubations for up to 96 h, as measured by DNA fragmentation and the release of LDH (data not shown). No difference in survival was seen between mock-transfected HD-MyZ cells and cells overexpressing a mutant, dominantnegative IkB (IkBdn), indicating that inhibition of NFkB did not sensitize cells to TNFa treatment (see below; data not shown). In contrast, 30% of LNCaP (prostate cancer) cells died at a concentration of 40 ng/ml TNFa within 72 h (data not shown), verifying that the TNFa used was bioactive. Unlike TNFa, the cytostatic drugs etoposide and epirubicin, as well as the cell-permeable, short-chain C 2 -ceramide, induced cell death in a dosedependent fashion in HD-MyZ cells, as assessed by measurement of DNA fragmentation and LDH release (Figure 1 ). Etoposide at concentrations of 0.75 and 1.0 mg/ml induced apoptosis within 72 h in 10.8 and 17.1% of HD-MyZ vector control cells (Figure 1a) . In HD-MyZ IkBdn cells, however, 37.6 and 47.3% of the cells were killed under the same conditions. Similar results were obtained when HD-MyZ mock and IkBdnexpressing cells were treated with 60 mM C 2 -ceramide. After 48 h of exposure to ceramide, HD-MyZ mock and IkBdn cells showed 5.6 and 34.8% apoptosis, respectively (Figure 1e ). Interestingly, no differences in apoptosis sensitivity between the mock and the IkBdn transfectants were seen in response to epirubicin (Figure 1c) .
To determine whether TNFa affected the sensitivity of HD-MyZ cells to apoptosis induced by cytotoxic drugs, we preincubated the cells with 20 ng/ml TNFa for 6 h and exposed them subsequently to different concentrations of etoposide, epirubicin or ceramide ( Figure  1a -f). The combination of drugs and TNFa led to a marked increase of cell death. Whereas 0.75 mg/ml etoposide alone induced apoptosis in 10.8% of HDMyZ vector control and 37.6% of the IkBdn-expressing cells, in both cell lines pretreatment with TNFa resulted in increased cell death, that is, of 20.8% in the HD-MyZ vector control or 49.3% in the IkBdn cells, respectively ( Figure 1a) . Likewise, epirubicin-induced apoptosis was approximately doubled from 24.6% (mock) or 20.1% (IkBdn) at 0.75 mg/ml epirubicin in the absence of TNFa to 39.0% (mock) or 39.1% apoptotic cells (IkBdn) when cells were pretreated with TNFa ( Figure 1c) . TNFa also enhanced ceramide-mediated apoptosis at 60 mM from 5.6 to 28.9% in HD-MyZ mock cells and from 34.8 to 50.5% in IkBdn cells (Figure 1e) .
A similar increase in cytotoxicity was observed when overall cell death was measured by the release of LDH (Figure 1b, d, f) . Thus, for all pro-apoptotic stimuli tested, TNFa acted as a sensitizing adjuvant, while TNFa by itself had no apoptotic activity in HD-MyZ cells. The potentiation of cytotoxicity observed upon TNFa pretreatment occurred via an NF-kB-independent mechanism, since the overexpression of the IkBdn did not affect the sensitizing effect of TNFa, although it completely abrogated NF-kB activation and cIAP-2/ HIAP-1 induction (Figure 3 ; ). Nevertheless, depletion of NF-kB signaling sensitized cells for apoptosis induction by etoposide and ceramide, but not by epirubicin (Figure 1 ; see also Figure 10 ).
Sensitization for drug-induced apoptosis by TNFa in myeloid leukemia cell lines
To explore whether the sensitizing effect of TNFa represents a general phenomenon, we treated various myeloid leukemia cell lines with epirubicin, etoposide and C 2 -ceramide after pretreatment with TNFa. We analysed the sensitizing efficiency of TNFa on two myeloid, CML-derived cell lines, K562 and EM3 (both derived from patients with chronic myeloid leukemia in blast crisis), and two cell lines derived from patients with acute myeloid leukemia (AML), KG-1 and OCI-AML2. Etoposide-induced apoptosis was detected via DNA fragmentation after 72 h in the presence or absence of 20 ng/ml TNFa (Figure 2a-d ). The pretreatment with TNFa increased the apoptosis of K562 and KG-1 cells treated with 2.5 mg/ml etoposide from 12.8 to 29.1% and from 14.6 to 42.3%, respectively (Figure 2a, b) . In a similiar fashion, TNFa augmented apoptosis induced by 1 mg/ml etoposide from 28.4 to 53.1% in EM3 cells and from 34.6 to 59.2% in OCI-AML2 cells (Figure 2c, d ). In contrast, L540 cells, a Hodgkin cell line, did not show this effect, even at higher TNFa concentrations (data not shown). These data suggest that the sensitizing effect of TNFa to chemotherapeutic drugs can be found in a variety of myeloid leukemic cells, but not necessarily in cells derived from other lineages.
Impact of TNFa on expression levels of apoptosisregulating genes
To analyse the mechanism of TNFa-mediated sensitization in drug-induced apoptosis, we determined the expression levels of IAP proteins, Bcl-x L and Bid in cultures exposed to TNFa. In contrast to our expectations, Figure 3a demonstrates that TNFa induced increased expression of HIAP-1 (cIAP-2), whereas the protein expression of the IAP proteins HIAP-2 (cIAP-1) and XIAP remained unaffected. Interestingly, the expression of the dominant-negative IkBa mutant in the HD-MyZ IkBdn cells abrogated the induction of (Figure 3b ). This demonstrates that HIAP-1, but not the other IAP genes investigated are subject to regulation through an NF-kB-dependent pathway in HD-MyZ cells. Moreover, neither Bcl-x L nor Bid protein levels were affected upon blocking of the NF-kB signaling pathway or treatment with TNFa. Both Bid and Bcl-x L showed a slight induction in the HD-MyZ mock transfectants, which was absent in the TNFa treated IkBdn cells. Thus, TNFa treatment results in enhanced expression of NF-kB-responsive antiapoptotic gene HIAP-1, and this is prevented in the IkBdn cells. In fact, these findings may explain the intrinsic differences in apoptosis sensitivities between the mock-transfected and the IkBdn-transfected HD-MyZ cells. Nevertheless, induction of antiapoptotic genes by TNFa cannot explain the sensitizing effect of TNFa on drug-induced apoptosis. To this end, we investigated the impact of TNFa on activation of the mitochondrial apoptosis pathway and activation of inducer and effector caspases.
Activation of caspases in HD-MyZ cells exposed to TNFa and chemotherapeutic drugs or ceramide
Activation of the effector caspase-3 is a central event for the execution of apoptosis (Carpentier and Beyaert, 1999; Friedrich et al., 2001; Ja¨nicke et al., 2001) . To elucidate the signaling steps involved in the sensitization of HD-MyZ cells by TNFa, we analysed the cleavage and activation of caspase-3. As shown by Western blot analysis, essentially no caspase-3 cleavage was observed in HD-MyZ-mock or IkBdn cells treated with TNFa alone (Figure 4a-c) . Exposure to etoposide moderately induced cleavage of caspase-3 (Figure 4a ). Caspase-3 cleavage was augmented by pretreatment of cells with TNFa. Again, the sensitizing effect of TNFa was NFkB-independent and could be observed in HD-MyZmock and IkBdn cells (Figure 4a ). HD-MyZ cells treated with C 2 -ceramide displayed no caspase-3 activation in mock-transfectants, but in NF-kB-blocked cells showed the protecting influence of NF-kB for C 2 -ceramide-induced apoptosis (Figure 4c ). Pretreatment with TNFa increased the amount of active caspase-3, and this effect was most prominent in HD-MyZ-IkBdn cells (Figure 4c ). Exposure to epirubicin led to a similar extent of caspase-3 cleavage in HD-MyZ IkBdn and control cells. In the same line, pretreatment with TNFa resulted in a higher amount of caspase-3 cleavage in both cell lines (Figure 4b ). To exclude that changes in the expression of Bcl-2 family proteins were responsible for the sensitizing effect of TNFa, we determined Bcl-2 and Bax expression by Western blot analysis. However, no significant changes in the expression levels were detectable after drug and TNFa treatment (Figure 4a-c) .
The same pattern of caspase-3 activation was detected even at earlier time points by means of a colorimetric enzyme assay using Ac-DEVD-pNA as substrate. Caspase-3 activity was analysed in lysates from cells Staining of the membrane with ethidium bromide to visualize the levels of 28 and 18s rRNA was used as a loading control treated with either 0.75 mg/ml etoposide, 0.5 mg/ml epirubicin for 48 h, or with 60 mM ceramide for 22 h (Figure 4d-f) . In all cases, the combination of chemotherapeutic drugs or ceramide with TNFa increased caspase-3 activity as compared to cultures treated in the absence of TNFa. Thus, the increase in caspase-3 activities correlated with the higher levels of apoptosis after pretreatment with TNFa. Moreover, these results confirm that NF-kB protected HD-MyZ cells from killing induced by etoposide and ceramide, but not from epirubicin-induced cell death. Loss of NFkB activation in the HD-MyZ cells failed, however, to affect the sensitizing effect of TNFa on ceramide or drug-induced cell death and caspase-3 cleavage.
Pretreatment with TNFa does not increase caspase-8 activity
Proteolytic cleavage and activation of caspase-8 is induced by the recruitment of FADD and procaspase-8 into the death-inducing signaling complex following binding of TNFa to TNF-RI Wallach et al., 2002) . Interestingly, no active p18 cleavage fragments of caspase-8 were generated by TNFa at detectable levels with or without subsequent etoposide, epirubicin or ceramide treatment in the HD-MyZ cells (Figure 5a-c) . Moreover, no difference in caspase-8 cleavage was observed between HD-MyZ mock and IkBdn cells (Figure 5a-c) . Finally, we did not detect (Figure 5f ), no increase of caspase-8 activity was detectable in a colorimetric assay for enzyme activity using z-IETD-pNA as a substrate for caspase-8-like activity. Taken together, these results suggest that activation of caspase-8 is presumably not required for the sensitizing effect of TNFa. Another initiator caspase, procaspase-2, has been implicated in the death receptor pathway and was shown to associate with TNF-R complexes via the adaptor protein RAIDD through its CARD domain (Shearwin-Whyatt et al., 2000) . In addition, the initiation of stress-induced apoptosis was shown to be mediated through caspase-2 activation upstream of the mitochondria (Lassus et al., 2002) . To address this mechanism, we also analysed the pattern of caspase-2 activation in the HD-MyZ system. After treatment with TNFa alone, no caspase-2 activation was observed (Figure 5a-c) . In the presence of etoposide and epirubicin, the appearance of the active p14 fragment of caspase-2 was detected. Since no cleavage was seen after TNFa treatment alone, we assume that direct, TNFa-induced processing of caspase-2, for example, via RIP/RAIDD-mediated recruitment to the TNF receptor complex, is not responsible for the sensitizing effect of TNFa. Nevertheless, the druginduced cleavage of procaspase-2 was enhanced by pretreatment with TNFa, and this suggests that the sensitization by TNFa occurs upstream of caspase-2 cleavage and that caspase-2 participates in drug-induced apoptosis. Interestingly, no such effect was seen in the case of ceramide, thereby suggesting a different mode of action.
To exclude a cellular defect in the activation of caspase-8, in vitro activation of hypotonic cell-free extracts from untreated HD-MyZ mock and IkBdn cells was performed. Addition of cytochrome c and dATP to cytosolic extracts from both cell lines resulted in the rapid accumulation of IETDase as well as of DEVDase-specific activity (Figure 6a, b) . In the same extracts, activation of caspases by the use of exogenous cytochrome c and dATP led to the processing of caspase-8, as determined by Western blotting (Figure 6c ). Thus, cell-free extracts from HD-MyZ mock and IkBdn cells contained comparable amounts of inducible caspase-3-and -8-like activities.
Death receptor and mitochondrial pathways are interconnected via the activation of the Bcl-2 homologous BH3-only protein Bid (Li et al., 1998; Luo et al., 1998; Desagher et al., 1999) . Bid is directly cleaved by caspase-8, whereupon the BH3 domain-containing fragment of Bid triggers cytochrome c release. Processing of caspase-3 and -8 and cleavage of Bid to tBid were shown recently to be required for full release of cytochrome c and activation of the mitochondrial pathway during drug-induced apoptosis (von Haefen et al., 2003) . We therefore performed a Western blot analysis of Bid in cells treated with etoposide, epirubicin and ceramide in the presence or absence of TNFa (Figure 7 ). In agreement with the lack of caspase-8 processing, we did not observe a cleavage of full-length Bid when cells were exposed to TNFa alone or a combination of etposide (Figure 7a (Figure 7b ). This was, however, due to lower protein loading, as evidenced by the actin control.
Likewise, no tBid cleavage product was detectable in these analyses (data not shown).
To further support that the sensitization by TNFa is not mediated by caspase-8 in the present setting, we performed a functional analysis in which we (Figure 8b ). Similar data were obtained for etoposide-induced cell death (data not shown). Altogether, these experiments strongly suggest that the sensitizing effect of TNFa occurs via a caspase-8-independent pathway. Nevertheless, we observed that inhibition of caspase-8 by the peptide inhibitor led to a small but significant decrease of epirubicin-induced apoptosis after a 3-day culture (Figure 8b ). This inhibition of epirubicin-induced cell death was observed, however, in both the absence and presence of TNFa pretreatment. In a recent report, we demonstrated that caspase-8 is activated by a receptor-and FADDindependent mechanism downstream of the mitochondrial apoptosome and caspase-3 cleavage (Wieder et al., 2001a) . Furthermore, caspase-8 processing was shown to be required for full release of cytochrome c during drug-induced apoptosis (von Haefen et al., 2003) . Thus, the present data are well in line with the model that caspase-8 may function as a downstream amplificator caspase during drug-induced cell death.
Early loss of mitochondrial membrane potential and release of cytochrome c upon TNFa cotreatment
As the sensitizing effect of TNFa occurred independently from caspase-8/Bid processing, we analysed in the following experiments whether cotreatment with TNFa affected the mitochondrial pathway of apoptosis. The mitochondrial release of cytochrome c is an important event during apoptosis: cytoplasmic cytochrome c forms a complex with Apaf-1, resulting in the activation of procaspase-9 and subsequent activation of other caspases. To investigate the involvement of these mitochondrial events in the sensitization by TNFa, we exposed HD-MyZ cells to the different cytotoxic drugs (Figure 10c, d) . These transfectants were, as an internal control, compared with the IkBdn transfectants. As shown already in Figure 1 , inhibition of NF-kB activation by the IkBdn mutant sensitized HD-MyZ cells for etoposide, but not against epirubicininduced cell death. Again, the sensitization for druginduced apoptosis by TNFa was not affected by the IkBdn mutant. These data corroborate that the sensitizing effect of TNFa for drug-induced apoptosis is independent of NF-kB, but is nevertheless mediated through the mitochondrial pathway via a Bcl-x Lsensitive mechanism.
To evaluate further steps leading to the activation of caspases, we determined the cytochrome c distribution in the cytosol and mitochondria by subcellular fractionation and Western blot analysis. Cytochrome c was released prior to the onset of apoptosis and DNA fragmentation upon treatment with etoposide, epirubicin (after 40 h), or upon exposure to C 2 -ceramide (after 20 h), but not in untreated control cells (Figure 11a-c) . Pretreatment with TNFa efficiently increased cytochrome c release in etoposide-, epirubicin-or ceramide-mediated apoptosis. Since caspase-9 is the initiator protease triggered in the mitochondrial pathway, we analysed caspase-9 processing and activation. After treatment of cells with C 2 -ceramide with or without pretreatment with TNFa, caspase-9 cleavage was detected using an antibody specific to the proform of caspase-9 (Figure 11d ). Caspase-9 processing was most evident in IkBdn cells in which TNFa pretreatment led to a clear decrease of procaspase-9 levels (Figure 11d ) that were paralleled by an increase of caspase-9 enzyme activity as measured by a colorimetric assay ( Figure  11e ). Similar results were obtained with etoposide and epirubicin (data not shown). These results suggest that caspase-9 rather than caspase-8 is responsible for the Figure 9 Loss of mitochondrial membrane potential (DC m ) precedes apoptosis after treatment with cytostatic drugs and ceramide and is enhanced by preincubation with TNFa HD-MyZ mock transfectants, and IkBdn cells were preincubated with or without TNFa for 6 h and then treated with etoposide, epirubicin or ceramide. At 40 h after drug and 22 h after C 2 -ceramide treatment, the DC m was determined by flow cytometric analysis of cells stained with the potential-sensitive dye JC-1 (a-c). All data points represent the mean7s.d. (n ¼ 3)
TNFa sensitizes for anticancer drugs K Schmelz et al activation of downstream caspases during TNFamediated sensitization to drug-induced cell death. Furthermore, the loss of Dc m and the release of cytochrome c imply a central role of mitochondria in drug-induced apoptosis and in the sensitizing effect of TNFa.
In view of the enhanced caspase-2 cleavage in the presence of TNFa, we performed experiments to clarify whether procaspase-2 processing occurs upstream of the mitochondrial death pathway or in consequence of downstream events, for example, as a consequence of cleavage by effector caspases. To this end, Bcl-x L was expressed stably in HD-MyZ cells by the use of a retroviral vector (Figure 12a ). Bcl-x L -overexpressing After 40 h of treatment with chemotherapeutic drugs or 20 h of treatment with ceramide, subcellular fractions and whole-cell lysates were prepared and analysed by Western blotting using antibodies specific for cytochrome c (a-c) or caspase-9 (d). The blots were reprobed with a b-actin antibody to control for equal protein loading. Additionally, hypotonic lysates were prepared and hydrolysis of the colorimetric substrate LEHD-pNA was measured in duplicates to determine caspase-9-like activity. A representative result for ceramide from one out of three experiments is shown (e). Similar data (not shown) were obtained for etoposide and epirubicin TNFa sensitizes for anticancer drugs K Schmelz et al and mock-transfected HD-MyZ cells were then exposed to epirubicin or etoposide in the presence or absence of TNFa (Figure 12b , c). Caspase-2 processing was determined by disappearance of the procaspase-2 zymogen. Figure 12c clearly shows that Bcl-x L inhibits procaspase-2 processing. Moreover, the enhancement of procaspase-2 cleavage in TNFa-induced cultures was abrogated in the presence of Bcl-x L . This clearly places caspase-2 processing downstream of the mitochondrial activation and events such as cytochrome c release.
Activation of the sphingomyelin cycle upon exposure to TNFa
TNFa induces the production of ceramide in a wide variety of cells by stimulation of the sphingomyelin cycle (Kolesnick et al., 1994; Kro¨nke, 1999) . Exogenous ceramide itself can induce cells to undergo apoptosis . To analyse the role of ceramide in the sensitizing effect of TNFa, we measured sphingomyelin breakdown after TNFa treatment of HD-MyZ cells. At a concentration of 20 ng/ml, TNFa induced a transient decrease of sphingomyelin after 15 min in HD-MyZ mock and after 30 min in the IkBdn transfectants (Figure 13a ). At these time points, approximately 30% of the cellular sphingomyelin was hydrolysed, but no significant differences were detected between HD-MyZ vector control and IkBdn cells. Thus, the generation of ceramide was a fast event after TNFa treatment and occurred independently of NF-kB. The implication of the ceramide pathway in TNFa signaling provided the rationale to include exogenous C 2 -ceramide in the experiments described above. To this end, cells were pretreated by use of exogenous C 2 -ceramide to mimic the effect of TNFa in drug-induced apoptosis. However, unlike TNFa, 20 mM C 2 -ceramide failed to sensitize HD-MyZ cells to apoptosis induced by etoposide and epirubicin (Figure 13b, c) . Different concentrations of C 2 -ceramide yielded the same result and no sensitizing effect of C 2 -ceramide was observed (data not shown). Thus, ceramide could not substitute for TNFa, suggesting that it is not a major player for the sensitizing effect of TNFa.
Discussion
A wide variety of conditions can sensitize cells to TNFainduced death, such as overexpression of p53 and cMyc, exposure to staurosporine and interferon-g, or the inhibition of protein synthesis (Suffys et al., 1989; Beyaert et al., 1993; Shatrov et al., 2000; Wallach et al., 2002) . In contrast, only a few situations have been described in which TNFa itself sensitized cells for apoptosis. TNFa has been reported to enhance the sensitivity of HIV-infected U1 cells, but not noninfected cells, to natural killer and lymphokine-activated killer cell lysis (Fortis et al., 1999) . TNFa also increases the antitumor effects of radiation on glioma xenografts in mice (Gridley et al., 1997) or cultured prostate cancer cells (Kimura et al., 1999) . In this report, we show that TNFa markedly sensitized HD-MyZ cells for apoptosis induced by chemotherapeutic drugs and ceramide, while TNFa alone exerted no cytotoxic effect. Importantly, the sensitizing effect of TNFa was not restricted to the Hodgkin-derived cell line HD-MyZ, but could also be observed in a panel of cell lines of myeloid origin, which were strongly enhanced in their susceptibility to etoposide-induced apoptosis by TNFa. In HDMyZ cells, the sensitization was entirely independent of NF-kB and caspase-8, but involved an early loss of the mitochondrial membrane potential and caspase-9 activation.
In the pathway of TNFa-induced apoptosis, caspase-8 acts as the central initiator caspase . In addition, caspase-8 may further function as a downstream effector caspase, which may be involved in a mitochondrial amplication loop (Belka et al., 1999; Wesselborg et al., 1999; Wieder et al., 2001a) , presumably via cleavage of the BH3-only protein Bid (Belka et al., 2000; Belka et al., 2001) . Interestingly, we could not detect an increased caspase-8 activation or Bid cleavage upon pretreatment with TNFa when HD-MyZ cells were exposed to chemotherapeutic drugs. Furthermore, a caspase-8 inhibitor did not prevent the sensitizing effect by TNFa, while caspase-8-dependent apoptosis in Jurkat cells was efficiently inhibited. In addition, the sensitization by TNF did not correlate with cleavage of the caspase-8 in drug-treated HD-MyZ cells. Altogether, these results suggest that neither a direct nor a type-II-related death receptor pathway is involved in the sensitizing effect of TNFa. Therefore, the sensitizing effect of TNFa appears to differ from that mediated by TRAIL, since TRAIL mediates apoptosis and sensitization of cancer cells to anticancer drugs or ionizing irradiation through a strictly caspase-8/Biddependent mechanism (Belka et al., 2000; Perez and White, 2000; Sprick et al., 2002) .
There is ample evidence that apoptotic pathways triggered by death receptors and chemotherapeutic drugs are counteracted by NF-kB (Wallach et al., 2002) . As expected, NF-kB was protective against apoptosis induced by etoposide and ceramide in HDMyZ cells, and considerably less killing was observed in HD-MyZ mock transfectants than in IkBdn-overexpressing cells. Among other target genes, NF-kB has been found to induce the expression of cIAP-1 and cIAP-2, which promote cell survival (Busuttil et al., 2002) . Members of the IAP family may further suppress apoptosis by the direct inhibition of caspases (Roy et al., 1997; Wang et al., 1998) . Consequently, downregulation of these or additional antiapoptotic NF-kB target genes might be responsible for the increased susceptibility of HD-MyZ cells overexpressing IkBdn. Interestingly, inhibition of NF-kB in the IkBdn transfectants did not lead to increased cell death in response to epirubicin. The assessed LDH activity in comparison to DNA fragmentation enables to distinguish between apoptosis and necrosis, since TNF and cytostatic drugs may induce both apoptosis and necrosis Blagosklonny, 2000) . Epirubicin induced a higher percentage of LDH activity than DNA fragmentation by 72 h, suggesting a greater influence of necrosis and a different time course of cell death. This might be a possible explanation for the inability of NF-kB to protect cells against necrotic, epirubicin-induced damage. Since the TNFa-mediated increase of druginduced cell death and caspase activation was similar in mock transfectants and IkBdn cells, our data suggest that the TNFa-sensitizing effect is independent from NF-kB.
To dissect the signaling events underlying TNFmediated sensitization to apoptosis, we analysed the activation of the mitochondrial death machinery. TNFa pretreatment was found to cause an enhanced release of cytochrome c and increased mitochondrial permeability transition, resulting in a pronounced activation of caspase-9. These data indicate that the mitochondrial apoptotic pathway is used by TNFa as a sensitizer for chemotherapeutic drugs.
There are several potential mechanisms that could be involved in the potentiating effect of TNFa during druginduced apoptosis. One possibility is the induction of oxidative stress by the generation of reactive oxygen intermediates (ROIs). This TNFa-induced ROI formation has been implicated in cell death (Schulze-Osthoff et al., 1992) . It has been shown that: (i) TNFa-mediated ROI formation is strictly correlated with cytotoxicity, (ii) TNFa-induced ROIs are produced in mitochondria as a result of its interference with the electron flow and that (iii) ROIs are induced before the occurrence of irreversible cell damage (Schulze-Osthoff et al., 1992 Goossens et al., 1995) . Interestingly, ROI generation by TNFa does not involve caspase-8 activation and is also observed following overexpression of a dominant-negative FADD mutant that completely blocks caspase activation and apoptotic alterations of cell death (Khwaja and Taton, 1999; Luschen et al., 2000) . Thus, the generation of ROIs and the depletion of antioxidants, which may be not cytotoxic per se, may potentiate mitochondrial damage and amplify cytochrome c release and caspase-9 activation in response to drug treatment. Recently, Gottlieb et al. (2000) showed that high levels of ROIs are produced during TNFainduced apoptosis, which was efficiently prevented by antioxidants. This corroborates that ROI production is an important component of TNFa-induced mitochondrial alterations. Thus, ROI formation could be involved in the sensitizing effect on drug-induced apoptosis exerted by TNFa that takes place upstream of the mitochondria. Nevertheless, TNFa-induced ROI formation was inhibited by Bcl-x L (Gottlieb et al., 2000) , thereby indicating that ROI occurs secondary to mitochondrial activation.
Since sensitization for drug-induced apoptosis by TNFa was independent of NF-kB and caspase-8/Bid, we analysed the role of ceramide as a candidate for the enhanced mitochondrial alterations induced by a combined treatment. The ability of ceramides to initiate apoptosis in myeloid and lymphoid tumor cell lines as well as in normal lymphocytes is well known (Hannun, 1996; von Haefen et al., 2002) . Agonists such as TNFa and IL-1 activate sphingomyelinases, leading to ceramide accumulation (Hannun, 1996) . However, similar to stress-activated protein kinases, the precise role of ceramides in death receptor pathways is unclear. Ceramide generation has been located downstream of the death adaptor proteins TRADD and FADD and upstream of effector caspases (Schwandtner et al., 1998) . In this line, we have shown recently that ceramide induces caspase-independent activation of cytochrome c release and loss of Dc m through a Bax-dependent mechanism . Regardless of the exact mechanism of ceramide generation by TNFa, we observed a rapid activation of the sphingomyelin cycle after treatment with TNFa. Sphingomyelin breakdown was transient and preceded the onset of substantial apoptosis. Furthermore, TNFa-induced hydrolysis of sphingomyelin was observed in both HD-MyZ control cells and IkBdn cells, suggesting that ceramide production is not NF-kB regulated. To determine the importance of ceramide generation for the TNFa-sensitizing effect, we investigated whether exogenous C 2 -ceramide could mimic the effect of TNFa. C 2 -ceramide alone was not able to substitute for TNFa as a sensitizer for chemotherapeutic drugs. These data suggest that ceramide is generated upon drug exposure but does not mediate TNFa-mediated sensitization to chemotherapeutic drug-induced apoptosis.
An interesting possibility how TNFa may mediate sensitization for drug-induced apoptosis came from our observation that TNFa enhances cleavage of procaspase-2. Caspase-2 was recently demonstrated to link nuclear stress signals to the mitochondrial pathway of apoptosis (Lassus et al., 2002; Troy and Shelanski, 2003) . This involvement of caspase-2 in mediating nuclear stress signals is currently under controversial discussion. Opposing data are available from the very same cell system and transfectants that either show or decline involvement of caspase-2 in the signal transduction upon exposure to anticancer drugs (Droin et al., 2001; Robertson et al., 2002) . Our present data clearly show, however, that drug-induced processing of the caspase-2 zymogen occurs downstream of the mitochondria, as it could be inhibited by Bcl-x L . This indicates that caspase-2 processing is not involved in TNFamediated sensitization for drug-induced activation of the mitochondrial apoptosis pathway, but might play a Figure 14 Signaling model of TNFa-mediated sensitization for drug-induced apoptosis. Treatment of cells with TNFa sensitizes for drug-induced cytochrome c release, loss of mitochondrial membrane potential, cleavage of caspase-2, -3 and -9, but not of caspase-8 or Bid. NF-kB inhibits apoptosis by inducing expression of antiapoptotic factors such as the Bcl-2 homologs Bcl-x L and A1, or inhibitor of apoptosis proteins (IAPs). The sensitization by TNFa was shown to be independent of NF-kB signaling or caspase-8/Bid cleavage, but was completely abrogated by overexpression of Bclx L . Caspase-2 processing was inhibited by overexpression of Bcl-x L and therefore occurs downstream of the mitochondria. Casp: caspase TNFa sensitizes for anticancer drugs K Schmelz et al role in the effector phase. These results are well in vein with data showing impaired caspase-2 processing in Bax-deficient cells (He et al., 2004) . In addition, caspase-2 was shown previously to be cleaved in a APAF-1/ caspase-9 and -3 dependent manner both in a cell-free system (Slee et al., 1999) and in thymocyte or neuronal apoptosis (O'Reilly et al., 2002) . In TNFa-induced cell death, caspase-2 processing occurred preferentially through a caspase-3-dependent mechanism (Paroni et al., 2001) . Thus, the majority of data indicate that, in most instances, caspase-2 is processed during the execution stage of apoptosis. To summarize these findings, a signaling model of TNFa-mediated sensitization for drug-induced apoptosis is shown in Figure 14 .
Notably, the sensitizing effect of TNFa was not only observed in HD-MyZ cells but also in other myeloid cell lines. Since the prognosis for patients with relapsed myeloid leukemia is very poor, there is a need for agents that sensitize tumor cells to chemotherapy. TNFa or small molecules mediating such a sensitizing effect may be of potential therapeutic value. Current studies are therefore investigating the detailed molecular mechanisms of TNFa-mediated sensitization to drug-induced apoptosis in order to evaluate the potential applications of this effect in antitumor therapy. In this vein, it appears particularly promising that TNFa-mediated sensitization occurs through signaling mechanisms that differ significantly from TRAIL-mediated effects in the cell systems investigated.
Materials and methods
Cell lines and cell culture
HD-MyZ cells were originally isolated from the pleural effusion of a 29-year-old patient with Hodgkin's disease of nodular sclerosing type (Bargou et al., 1993) . Immunofluorescence analysis revealed a myelomonocytoid phenotype such as expression of CD13 and CD68, and lack of lymphoid markers. Cells were transfected with a dominant-negative (dn) IkBa construct lacking the first 70 N-terminal amino acids and cloned in pcDNA3.1. Stable clones were selected with G418 as described earlier . Cell lines expressing comparable levels of mutant IkB were cloned by limiting dilution and identified by immunoblotting. By stable expression of IkBdn, it has been shown previously that constitutive NF-kB-RelA activation is essential for both proliferation and survival of HD-MyZ cells . The human chronic myeloid cell line EM3, the human acute myeloid leukemia cell lines KG-1 and OCI-AML2, and the Hodgkin cell line L540 were purchased from the 'Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH' (DSMZ, Braunschweig, Germany, www.dsmz.de). The human chronic myeloid cell line K562 was kindly provided by T Mokros and M Lipp (Max-Delbru¨ck-Centrum, Berlin, Germany). HDMyZ cells were cultured in RPMI 1640 medium containing 30% fetal calf serum (FCS) supplemented with 2 mM glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin at 371C in a humidified atmosphere with 5% CO 2 . OCI-AML2 were cultured in MEM-alpha medium containing 10% FCS, glutamine and antibiotics. All other cell lines were routinely cultured in RPMI 1640 medium containing 10% FCS, glutamine and antibiotics.
Stable expression of Bcl-x L by retroviral infection
HD-MyZ cells stably expressing Bcl-x L were generated by using the retroviral vector pBabe-Puro-Bcl-x L as described (Hasenja¨ger et al., 2004) . Culture supernatant of the virus producing packing cell line FLY-A13 (Cosset et al., 1995) was employed to infect HD-MyZ cells in the presence of 8 mg/ml polybrene (Sigma-Aldrich). Puromycin (1 mg/ml, Calbiochem, Bad Soden, Germany) was added 48 h later and following 3 weeks of selection stable transfectants were subcloned. Bcl-x L expression of several individual clones was determined by Western blot analysis.
Measurement of cell death
For determination of cell death, cells were preincubated with or without TNFa (20 ng/ml, Promocell, Heidelberg, Germany) in RPMI 1640 medium and 10% FCS. After 6 h, they were treated for a further 72 h with or without the indicated concentrations of etoposide or epirubicin (Pharmacia Upjohn, Erlangen, Germany) or for 48 h with N-acetylsphingosine (C 2 -ceramide) (Alexis, San Diego, USA). For analysis of DNA fragmentation, 1 Â 10 5 cells/well were seeded in 100 mm plates. Following TNFa and drug incubation, cells were trypsinized and fixed in 2% formaldehyde on ice for 30 min. After centrifugation, the cells were treated with 60% ethanol for 20 min on ice, washed in PBS and further incubated for 30 min with DNase-free RNase (50 mg/ml) at 371C. Cells were centrifuged again, resuspended in 200 ml PBS containing 50 mg/ml propidium iodide and subjected to flow cytometric measurement of apoptosis as described (Hemmati et al., 2002; Radetzki et al., 2002) . The cellular DNA content was measured with logarithmic amplification in the FL-3 channel of a FACScan equipped with the CELLQuest software (Becton Dickinson; Heidelberg, Germany). Data are given as percentage of hypodiploid cells, that is, cells in sub-G1, reflecting the number of apoptotic cells. Cytotoxicity was measured by the release of cytosolic lactate dehydrogenase (LDH) as described (Wieder et al., 2001a, b) . In brief, cells were treated with different concentrations of the respective drugs. After different times of incubation, LDH activity was measured in the culture supernatants using the Cytotoxicity Detection Kit according to the manufacturer's instructions (Roche Molecular Biochemicals, Mannheim, Germany). The maximum release of LDH was determined by lysing the cells with 0.1% Triton X-100 in PBS. The percentage of LDH release in the samples represents the ratio of LDH activity in the supernatants relative to the total enzyme activity.
Measurement of cell death in the presence of caspase inhibitor
For inhibition of caspase-8, the cell-permeable inhibitor z-IETD-fmk (Enzyme Systems Product, Livermore, USA) was employed. Stock solutions of 20 mM were prepared in DMSO. 10 5 cells/well were seeded in 10 cm plates and pretreated with 20 mM z-IETD-fmk for 2 h. After incubation for 6 h in the presence or absence of TNFa (20 ng/ml, Promocell, Heidelberg, Germany), 0.5 mg/ml epirubicin (from Pharmacia Upjohn, Erlangen, Germany) was added. The inhibitor treatment was repeated after 36 h. Finally, cell death was determined by flow cytometric analysis of hypodiploid DNA content after 72 h as described above. As a positive control, Jurkat cells were treated with anti-CD95 mab immobilized to plastic to achieve strong receptor crosslinking (clone APO-1 IgG3 Dhein et al., 1994) , coating at 5 mg/ml overnight at 41C) for 24 h in the presence or absence of z-IETD-fmk (20 or 50 mM). Cell death in the Jurkat cells was determined by staining with Annexin-V-FITC or, in the HDMyZ cells, by measuring the cellular DNA content and the percentage of subG1 cells.
Measurement of caspase activity
Cytosolic extracts were prepared from HD-MyZ mock and HD-MyZ IkBdn cells as described (Wieder et al., 2001a) . Briefly, cells were washed with ice-cold buffer A (20 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM DTT) and resuspended in 1 volume of buffer A. Cells were incubated on ice for 20 min and then extracted by passage through a 26-gauge needle. Efficient disrupture of cells was controlled with trypan blue staining. Cell extracts were cleared by centrifugation at 16 000 g for 30 min and the resulting supernatants were stored at À801C. For initiating in vitro caspase activation, 1 mM DTT, 1 mM horse heart cytochrome c (Sigma) and 1 mM dATP were added and the extracts were incubated at 371C for 60 min. Proteolytic activity for caspase-3, -8 and -9 was assayed by the release of p-nitroanilide (pNA) from DEVD-, IETD-and LEHD-containing peptides (Calbiochem, Bad Soden, Germany) using an automated plate reader (SLT Labinstruments, Crailsheim, Germany) (Essmann et al., 2000) .
Measurement of the mitochondrial transmembrane potential and cytochrome c release Subcellular fractionation and purification of cytosolic fractions were performed using digitonin to permeabilize the cytoplasmic membrane. Briefly, cells were harvested and permeabilized in a buffer containing 100 mM sucrose, 20 mM MOPS, 1 mM EGTA, 1 mM PMSF and 0.75 mg/ml digitonin (Calbiochem). Cells were incubated on ice for 30 min and centrifuged at 16 000 g to collect the cytosolic supernatant. In all, 50 mg of the cytosolic fraction was subjected to SDS-PAGE and immunoblot analysis with an antibody against cytochrome c as described below.
For flow cytometric analysis of the mitochondrial membrane potential, cells were collected by centrifugation at 300 g and stained with 2.5 mg/ml of the potential-sensitive dye 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethyl-benzimidazolylcarbocyanine iodide (JC-1; Molecular Probes, Eugene, USA). Cells with low membrane potential were considered as undergoing apoptosis and are given as the percentage of the total cell population (Radetzki et al., 2002) .
Labeling of cells and sphingomyelin quantitation
Sphingomyelin was quantified with Streptomyces sphingomyelinase (Sigma, Deisenhofen, Germany) in order to release incorporated radiolabelled phosphocholine (Geilen et al., 1996) . In the experiments, 1 Â 10 5 cells were seeded in 10 cm plates and incubated for 72 h in medium containing 3.7 Â 10 4 Bq/ml [methyl-3 H]choline (Amersham, Braunschweig, Germany). Cells were washed twice with PBS and treated with TNFa for different time periods. After the incubation, the cells were washed with ice-cold PBS, harvested at 41C and subsequently freeze-dried. Total cellular lipids were extracted by the method of Bligh and Dyer (1959) . The lipid extracts were incubated with 1 U/ml sphingomyelinase to detect the release of [ 3 H]phosphocholine as described elsewhere (Wieder et al., 1998) .
Western blot analysis
Whole-cell lysates were prepared from 6 Â 10 5 cells in a buffer containing 50 mM Tris (pH 7.5), 1% Triton X-100, 270 mM sucrose and the protease inhibitors aprotinin (10 mg/ml), leupeptin (10 mg/ml) and PMSF (2 mM) as described (Essmann et al., 2000) . For analysing caspase-9 cleavage, cell lysates were prepared in Laemmli buffer containing 62.5 mM Tris, pH 6.6, 2% SDS and 10% glycerol. After normalization for total protein content (50 mg per lane), samples were subjected to SDS-PAGE and immunoblotted using rabbit polyclonal antibodies for caspase-2, -3 and -9 and murine monoclonal antibodies for cytochrome c, FADD (all from BD Pharmingen, Hamburg, Germany), rabbit polyclonal antibodies against Bid, HIAP-1, HIAP-2 (Trevigen, Gaithersburg, USA), murine monoclonal antibodies against Bcl-x L and XIAP (BD Transduction Laboratories, Los Angeles, CA, USA) and murine monoclonals against Bax (Trevigen) and caspase-8 Wieder et al., 2001a) as described (Essmann et al., 2000) . The anti-actin rabbit polyclonal antiserum was from Sigma-Aldrich. Horseradish peroxidase-conjugated secondary antibodies were obtained from Promega (Mannheim, Germany).
Northern blot analysis
Northern blot analysis was performed as described (Daniel et al., 1997) . In brief, total cellular RNA was prepared using TRIZOL reagent (Invitrogen, Heidelberg, Germany). Total RNA (20 mg) was separated on a 1.2% agarose gel containing 1.1% formaldehyde, transferred to a nylon membrane, and UV-crosslinked (1200 kcal, Stratalinker, Stratagene, La Jolla, USA). For hybridization, a HIAP-1 fragment was amplified by PCR using the following primers: HIAP-1 sense 5 0 GCT GGA TCC GCC GCC AGC CAT GAA CAT AGT AGA AAA CAG C 3 0 , antisense 5 0 CAG GCT ATC GAT TGG TTC TTC TTC ATG AAA GAA ATG TAC G 3 0 and labelled with a 32 PdCTP using a megaprime labelling kit (Amersham, Freiburg, Germany) . Hybridization of the membrane was performed at 681C overnight and visualized by autoradiography.
